The results of new analyses carried out on the FIRE-3 trial concerning the predictive role of the mir-31-3p marker in metastatic colorectal cancer will be presented at the 2016 congress of the European Society of Medical Oncology (ESMO) to be held in Copenhagen from October 7 to 12.

Professor Pierre Laurent-Puig, MD, PhD, Physician at the Biochemistry Department of the Georges Pompidou European Hospital (Paris) and Director of the Inserm UMR-S775 research unit at the Paris Descartes University of Medicine, will detail these new findings on the ability of miR-31-3p to predict response to Cetuximab treatment during a proffered session on Monday October 10 at 9:15 (Copenhagen Room, North Hall of the Bella Center).

Click here for more details: https://cslide.ctimeetingtech.com/library/esmo/browse/search/Htr